COVID-19

Phase 2 trial that tested use of monoclonal antibodies in patients with mild or moderate COVID-19. Patients who received LY-CoV555 hat lower viral titers and slightly lower severity of symptoms compared to placebo.

In this systematic review 936 neonates from mothers with coronavirus disease 2019, 27 neonates had a positive result for severe acute respiratory syndrome coronavirus 2 viral RNA test using nasopharyngeal swab, indicating a pooled proportion of 3.2% for vertical transmission.

The COVID-19 pandemic has placed extreme stress on the national health care system. As the epidemiology of COVID-19 evolves, obstetrical care providers must manage pregnant patients with COVID-19 in the setting of little to no experience or rigorous data from which to develop protocols and guidance.

In this Swiss multi-center study 47 patients after mild/moderate and 66 patients after severe/critical SARS-CoV-2 infection were followed up 4 months after recovery. In the patient group with a severe/critical course there were significantly more patients with a higher BMI, higher age, hypertension, diabetes and renal failure. A severe/critical condition during COVID-19 was associated with decreased pulmonary function as assessed by predicted % diffusion of carbon monoxide (DLCO), reduced distance during a 6 minutes walking test and exercise induced blood oxygen desaturation at 4 months follow up. Mosaic hypoattenuation in chest CT was significantly associated with severe/critical disease progression of COVID-19. Importantly, predicted % DLCO was the strongest and most important correlate for a severe/critical condition during COVID-19 infection, which may explain the reduced walking distance and desaturation during exercise. According to the authors this is the first European prospective longitudinal cohort study to understand the sequelae and different functional trajectories of COVID-19 patients.

Analysis of persisting anti-SARS CoV2 humoral, B- and T-cell immunity in 188 patients with mild to moderate COVID-Infection

Phase III results for the second COVID-19 mRNA vaccine (Moderna, mRNA-1273) demonstrate a similar performance compared with the Pfizer/Biontech BNT162b2 vaccine. Overall vaccine efficacy over 2 months after dose 2 was 94.1% with no differences according to gender, ethnicity and presence of risk factors. Efficacy > 65 years was somewhat lower (86%). Reactogenicity as to be expected, no severe adverse events reported.

Postponing the treatment of patients with symptomatic aortic stenosis increases the risk of worse patient outcome.

In this comparison between man and machine, an Artificial Intelligence (AI) algorithm outplayed human radiologists in classifying chest radiographs into “normal”, “COVID-19 pneumonia”, and “other pneumonia”.

Case series with one of the first series of patients with COVID-19 undergoing abdominal surgery. Illustrative is the visualization of SARS-CoV2 in the GI-Tract.

This is a comprehensive report of the Pfizer/ BioNTech vaccine product tested in a randomized trial (43'448 participants who received the vaccine or placebo injection). Based on 170 laboratory-confirmed infections, vaccine efficacy was 95% (90%–98%) for more than 7 days after a second dose of vaccine. Subgroup analyses for the age group over 65, gender and obesity category show similar vaccine efficacy estimates (all over 90% although with more uncertainty). The safety profile of the vaccine was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.